Printer Friendly

Preclinical Data on ARIAD's Novel Kinase Inhibitor to Be Presented at ASH Annual Meeting.

CAMBRIDGE, Mass. -- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that collaborating investigators from ARIAD, the Howard Hughes Medical Institute, and the Oregon Health and Science University will present data from preclinical studies on AP24534, a novel kinase inhibitor, at the 48th Annual Meeting of the American Society of Hematology in Orlando, Florida, December 9 to 12, 2006.

"These studies illustrate the progress we have made in preclinical drug discovery over the past year and highlight the potential for these new molecularly targeted compounds to expand our oncology pipeline," said Timothy P. Clackson, Ph.D., chief scientific officer of ARIAD.

The schedule and meeting place for the session, together with the abstract number, is listed below:

Sunday, December 10, 2006 at 9:00 a.m. to 8:00 p.m.

Session Title: Chronic Myeloid Leukemia: New Drugs

Abstract No. 2180; Poster Presentation (Board No. 358-II)

"Orally Active Inhibitors of the Imatinib-Resistant Bcr-Abl Mutant T315I"

Presenter: William C. Shakespeare, Ph.D., ARIAD

Location: Hall E1 of the West Building


ARIAD is engaged in the discovery and development of breakthrough medicines to treat cancer by regulating cell signaling with small molecules. The Company is developing a comprehensive approach to patients with cancer that addresses the greatest medical need - aggressive and advanced-stage cancers for which current treatments are inadequate. Medinol Ltd. also is developing stents and other medical devices that deliver ARIAD's lead cancer product candidate to prevent reblockage at sites of vascular injury following stent-assisted angioplasty. ARIAD has an exclusive license to pioneering technology and patents related to certain NF-I*B treatment methods, and the discovery and development of drugs to regulate NF-I*B cell-signaling activity, which may be useful in treating certain diseases. Additional information about ARIAD can be found on the web at

Some of the matters discussed herein are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are identified by the use of words such as "may", "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Such statements are based on management's expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such forward-looking statements. These risks include, but are not limited to, risks and uncertainties regarding our ability to accurately estimate the timing and actual R&D expenses and other costs associated with the preclinical and clinical development and manufacture of our product candidates, including our product candidate referred to in this press release, the adequacy of our capital resources and the availability of additional funding, risks and uncertainties regarding our ability to manufacture or have manufactured our product candidates on a commercial scale, risks and uncertainties regarding our ability to successfully recruit centers, enroll patients and conduct clinical studies of product, risks and uncertainties that clinical trial results at any phase of development, may be adverse or may not be predictive of future results or lead to regulatory approval of any of our or any partner's product candidates, risks and uncertainties of third-party intellectual property claims relating to our and any partner's product candidates, risks and uncertainties related to the potential acquisition of or other strategic transaction regarding the minority stockholders' interests in our 80%-owned subsidiary, ARIAD Gene Therapeutics, Inc., and risks and uncertainties relating to regulatory oversight, the timing, scope, cost and outcome of legal and patent office proceedings, litigation, prosecution and re-examination proceedings concerning our NF-I*B patent portfolio, future capital needs, key employees, dependence on collaborators and manufacturers, markets, economic conditions, products, services, prices, reimbursement rates, competition and other factors detailed in the Company's public filings with the Securities and Exchange Commission (SEC), including ARIAD's Quarterly Report on Form 10-Q for the period ended September 30, 2006, as updated from time to time in our subsequent periodic and current reports filed with the SEC. The information contained in this document is believed to be current as of the date of original issue. The Company does not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in the Company's expectations, except as required by law.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Dec 4, 2006
Previous Article:Cheryl Waybright Joins LEVEL5 as Senior Project Development Manager.
Next Article:Leading Paper Goods Manufacturers Turn to ToolsGroup's DPM Inventory Optimization Solution.

Related Articles
New Clinical Data on ARIAD'S Novel mTOR Inhibitor, AP23573, to Be Presented at Upcoming Oncology Meetings.
ARIAD Announces Initial Results of Phase 1b Clinical Trial of Oral AP23573 in Patients with Relapsed and/or Refractory Cancers.
INNOVIVE Pharmaceuticals Announces Data from Oncology Drug Programs to be Presented at American Association for Cancer Research Annual Meeting.
Cyclacel Pharmaceuticals to Present Preclinical Data on Sapacitabine and Seliciclib at AACR.
INNOVIVE Pharmaceuticals Announces Additional Data Presentations at American Association for Cancer Research Annual Meeting.
INNOVIVE Pharmaceuticals Announces Interim Phase I Data on INNO-406 for the Treatment of Gleevec-resistant or Intolerant Chronic Myelogenous Leukemia.
Gloucester Pharmaceuticals Reports on Romidepsin and Erlotinib Combination in Non-Small Cell Lung Cancer Presented at American Association of Cancer...
Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting.
INNOVIVE Pharmaceuticals to Present Interim Data from Phase I Study of INNO-406 at the American Society of Clinical Oncology Annual Meeting.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters